Why use the EQ-5D? What are the alternatives?. What are the alternatives for Direct valuation? Other VAS Time Trade-Off Standard Gamble Willingness to.

Slides:



Advertisements
Similar presentations
Comparing different treatments How can we decide?.
Advertisements

Measuring outcomes Emma Frew October Measuring outcomes Learning objectives By the end of the session students should be able to – Explain how different.
Emma Frew Introduction to health economics, MSc HEHP, October 2012 Outcomes: part II.
1 Could there be a single European EQ tariff? Jan J.V. Busschbach, Ph.D. Former address: –iMTA, Erasmus university Present address: –Medical Psychology.
COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
Scaling Session Measurement implies “assigning numbers to objects or events…” Distinguish two levels: we can assign numbers to the response levels for.
1 The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 A Health Economic View on Borderline Personality Disorder Prof. dr. Jan Busschbach Viersprong Institute for studies on Personality Disorders Medical.
Big Q and Little Q revisited Christopher McCabe PhD Capital Health Endowed Research Chair in Emergency Medicine Research.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
Using a discrete choice experiment with duration to estimate values for health states on the QALY scale Nick Bansback Assistant Professor School of Population.
Utility Assessment HINF Medical Methodologies Session 4.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
Health Economics II –2010 Health Economic Evaluations Part III Lecture 2 Cost-effectiveness analysis QALYs and cost-utility analysis Nils-Olov Stålhammar.
Valuing Health Daniel M. Hausman University of Wisconsin-Madison October 19, 2009.
Modelling Cardinal Utilities from Ordinal Utility data: An exploratory analysis Peter Gilks, Chris McCabe, John Brazier, Aki Tsuchiya, Josh Solomon.
Utilising rank and DCE data to value health status on the ‘QALY’ scale using conventional and Bayesian methods John Brazier and Theresa Cain with Aki Tsuchiya.
Quality of life Assessment introduction
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
1 EuroQol EQ-5D Jan J. V. Busschbach, Ph.D Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Department of Medical.
Measuring benefits Morris et al (2012) Ch Measuring benefits To perform an economic evaluation, we need to have information of the benefits and.
Measuring and valuing health outcome Montarat Thavorncharoensap, Ph.D. 1: Faculty of Pharmacy, Mahidol University 2. HITAP, Thailand.
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
Introduction to Effectiveness, Patient Preferences and Utilities Patsi Sinnott, PT, PhD, MPH HERC Economics Course May 6, 2009.
1 Health Economics  Comparing different allocations  Should we spent our money on Wheel chairs Screening for cancer  Comparing costs  Comparing outcome.
Measuring the “Q” in QALYs for cost- effectiveness analysis: the EuroQol Group’s approach Valuing health outcomes for healthcare decision making using.
Overview of the EQ-5D Purpose and origins of the descriptive system.
1 The valuation of disease-specific questionnaires for QALY analysis  To rescue data in absence of an utility measure  Growth hormone deficiency in adults.
Is healthcare any good for patients? Measuring health outcomes using EQ-5D Professor Paul Kind Principal Investigator Outcomes Research Group Centre for.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 11: Cost-utility analysis – Part 4.
New and ongoing areas of research In the EuroQol Group.
University of Minnesota Medical Technology Evaluation and Market Research Department of Healthcare Management Course: MILI/PUBH 6589 Spring Semester, 2013.
1 Patient values or values from the general public.
1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 Interactive introduction in Quality of life Assessment Jan J. v. Busschbach, Ph.D. Department of Medical Psychology and Psychotherapy, Erasmus MC
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
The experience of Denmark with Summary Measures of Population Health 7 th Meeting of the Task Force on Health Expectancies Luxembourg, 2 December 2008.
Patsi Sinnott, PT, PhD, MPH HERC Economics Course April 7, 2010 Introduction to Effectiveness, Patient Preferences and Utilities.
Overview of Health-Related Quality of Life Measures May 22, 2014 (1:00 – 2:00 PDT) Kaiser Methods Webinar Series 1 Ron D.Hays, Ph.D.
Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong.
Cost-Effectiveness of Psychotherapy for Personality Disorders Soeteman, Busschbach, Verheul.
Cost-effectiveness in the quest to convince the outside world Dr. Jan Busschbach De Viersprong Erasmus MC
1 Health outcome valuation study in Thailand Sirinart Tongsiri Research degree student Health Services Research Unit, Public Health & Policy Department.
Using a Discrete Choice Experiment to Value the EQ-5D-5L in Canada Nick Bansback Assistant Professor School of Population and Public Health, University.
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
Applying Expectancy-value Model to understand Health Preference An Exploratory Study Xu-Hao Zhang Department of Pharmacy National University of Singapore.
Hermann P. G. Schneider, Alastair H. MacLennan and David Feeny
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
Thirty down, only ten to go?! Awareness and influence of a 10-year time frame in TTO Floor van Nooten, Xander Koolman, Werner Brouwer 1 A paper introduced.
Cost-Effectiveness of Psychotherapy (for Personality Disorders) Prof. dr. Jan van Busschbach.
Values Lower Than Death Jan J. v. Busschbach, Ph.D. –Erasmus University Rotterdam institute for Medical Technology Assessment (iMTA) PO box DR.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
Effect of framing of death on health state values obtained from DCEs Dr. Esther W. de Bekker-Grob by Jonker, de.
1 Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Heidi Livingstone, Senior Public Involvement Adviser.
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
1 VAS, SG, TTO and PTO An Interactive Introduction.
Canadian TTO Valuations of the EQ-5D-5L: East versus West Differences
Table 1. Characteristics of generic HRQOL assessments in adult physical activity research Peter D. Hart et al. Systematic Review of Health-Related Quality.
1 Utilization of Quality of Life Research in Decision-Making and Policy  Prof. Dr. Jan J.V. Busschbach  Erasmus MC, Rotterdam, The Netherlands  Section.
Professor Nancy J. Devlin Office of Health Economics Royal Statistical Society June 18 th 2015 Measuring and ‘valuing’ patient reported health.
Prof. Dr. Jan J.V. Busschbach
Effect of framing of death on health state values obtained from DCEs
The valuation of disease-specific questionnaires for QALY analysis
Is healthcare any good for patients
Measuring outcomes Emma Frew October 2012.
How to Measure Quality of Life
Presentation transcript:

Why use the EQ-5D? What are the alternatives?

What are the alternatives for Direct valuation? Other VAS Time Trade-Off Standard Gamble Willingness to pay Difficult… –Paired comparisons –DCE etc

Visual Analogue Scale VAS –Also called “category scaling” –From psychological research “How is your quality of life?” “X” marks the spot –Rescale to [0..1] Different anchor point possible: –Normal health (1.0) versus dead (0.0) –Best imaginable health versus worse imaginable health Dead Normal health X

Time Trade-Off TTO Wheelchair –With a life expectancy: 50 years How many years would you trade-off for a cure? –Max. trade-off is 10 years QALY(wheel) = QALY(healthy) –Y * V(wheel) = Y * V(healthy) –50 V(wheel) = 40 * 1 V(wheel) =.8

Standard Gamble SG Wheelchair Life expectancy is not important here How much are risk on death are you prepared to take for a cure? –Max. risk is 20% –wheels = (100%-20%) life on feet –V(Wheels) = 80% or.80

Willingness to pay Cost benefit analyis Revealed preferences –Look in market how much subject are willing to pay –Different situations give different results –Weighted by in income Conclusion: –the validity of cost benefit analysis is not sufficient

Alternatives for indirect measurements MOBILITY  I have no problems in walking about  I have some problems in walking about  I am confined to bed SELF-CARE  I have no problems with self-care  I have some problems washing or dressing myself  I am unable to wash or dress myself USUAL ACTIVITIES (e.g. work, study, housework family or leisure activities)  I have no problems with performing my usual activities  I have some problems with performing my usual activities  I am unable to perform my usual activities PAIN/DISCOMFORT  I have no pain or discomfort  I have moderate pain or discomfort  I have extreme pain or discomfort ANXIETY/DEPRESSION  I am not anxious or depressed  I am moderately anxious or depressed  I am extremely anxious or depressed

Validated questionnaires

The Rosser & Kind Index

The Rosser & Kind index Criticism on the Rosser & Kind index –Sensitivity (only 30 health states) New initiatives –Higher sensitivity (more then 30 states) EuroQol Group –EQ-5D-3L and the EQ-5D-5L McMaster University –Health Utility Index 2 & 3 SF-36 –SF-6D

Health Utility Index Developed from pediatric care –Strong proxy versions Symptom driven: –“Outside the skin” instead of “inside the skin” EQ-5D: “problems with daily activity” HUI: “Unable to read ordinary newsprint…” Commercial –All user have to pay 35 Translations

HUI 2

HUI 3

Increasing number of health states

No longer value all states Impossible to value all health states –If one uses more than 30 health states Estimated the value of the other health states with statistical techniques –Statistically inferred strategies Regression techniques EuroQol, Quality of Well-Being Scale (QWB) –Explicitly decomposed methods Multi Attribute Utility Theory (MAUT) Health Utility Index (HUI)

Statistically inferred strategies Value a sample of states empirically Extrapolation –Statistical methods, like linear regression –11111 = 1.00 –11113 =.70 –11112 = ?

Statistically inferred strategies EuroQol –EQ-5D: 5 dimensions of health –245 health states Quality of Well-Being scale (QWB) –4 dimensions of health –2200 health states plus 22 additional symptoms SF-36 –SF-6D: 6 dimensions of health – health states

Explicitly Decomposed Methods Value dimensions separately –Between the dimensions –What is the relative value of: Mobility…... 20% Mood……….. 15% Self care.….24% Value the levels –Within the dimensions –What is the relative value of Some problems with walking…..80% Much problems with walking……50% Unable to walk………..……………….10% = 1 - (0.20 x ( )) = 0.96

Explicitly Decomposed Methods Combine values of dimensions and levels with specific assumptions –Multi Attribute Utility Theory (MAUT) Mutual utility independence Structural independence

Explicitly Decomposed Methods Health Utilities Index (Mark 2 & 3) –Torrance at McMaster –8 dimensions –Mark 2: health states –Mark 3: health states The 15-D –Sintonen H. –15 dimensions –3,052,000,000 health states (3 billion)

More health states, higher sensitivity ? (1) EuroQol criticised for low sensitivity –Low number of dimensions Development of EQ-5D plus cognitive dimension –Low number of levels (3) Gab between best and in-between level

More health states, higher sensitivity ? (2) Little published evidence –Sensitivity EQ-5D < SF-36 Compared as profile, not as utility measure –Sensitivity EQ-5D  HUI Sensitivity  the number of health states –How well maps the classification system the illness? –How valid is the modelling? –How valid is the valuation?

More health states, more assumptions General public values at the most 50 states The ratios empirical (50) versus extrapolated –Rosser & Kind1:1 –EuroQol1:5 –QWB1:44 –SF-361:180 –HUI (Mark III)1:19,400 –15D1:610,000,000 What is the critical ratio for a valid validation?

Conflicting evidence sensitivity SF-36 Liver transplantation, Longworth et al., 2001

SF-36 as utility instrument Transformed into SF6D SG N = 610 Inconsistencies in model – health states –regression technique stressed to the edge Floor effect in SF6D

Collapsing levels SF-6D Many levels are taken together –If PF=2decrement: –If PF=3decrement: –If RL=2decrement: –If RL=3decrement: –If RL=4decrement:

SF-6D loses a lot of levels Levels clas.system and actual levels –PF6 5 –RL 42 –SF 55 –PN 65 –MH 54 –VI 53 Levels in clas. system: –6x4x5x6x5x5 Actual levels: 480 –5x2x5x5x4x3

Some levels in the SF-6D do not work…

EQ-5D Strong punts –Very sensitive in the low –Measures subjective burden (inside the skin) –Low administrative burden –Many translations –Cheap –Most used QALY questionnaire –Most international validations Weak points –Only there levels per dimensions –Insensitive in the high regions

HUI Strong punts –Sensitive –Measures objective burden (outside the skin) –Well developed proxy versions –Well developed child versions Weak points –Expensive –Only a few valuation studies

SF-6D Strong punts –Probably sensitive in the high regions –Often already include in trials (SF-36) –Many translations Weak points –Insensitive in the low regions –Only a few validation study –Might be expensive

Conclusions More states  better sensitivity The three leading questionnaires –have different strong and weak points